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Developing a practical means of reducing alloimmunization in chronically transfused patients would be of significant clinical 
benefit. Immunocamouflaging red blood cells (RBCs) by membrane grafting of methoxypoly(ethylene glycol) (mPEG) may 
reduce the risk of allo-immunization. The results of this study showed that antibody recognition of non-ABO antigens was 
significantly reduced in an mPEG-dose- and polymer size-dependent manner, with higher molecular weight mPEGs providing 
better immunoprotection. Furthermore, in vivo immunogenicity was significantly reduced in mice serially transfused with 
mPEG-modified xenogeneic (sheep; sRBCs), allogeneic (C57Bl/6), or syngeneic (Balb/c) RBCs. Following a primary transfu-
sion of sRBCs, mice receiving mPEG-sRBCs showed a >90% reduction in anti-sRBC IgG antibody levels. After two transfu-
sions, mice receiving mPEG-sRBCs showed reductions of >80% in anti-sRBC IgG levels. Importantly, mPEG-modified 
autologous cells did not induce neoantigens or an immune (IgG or IgM) response. These data suggest that the global immuno-
camouflage of RBCs by polymer grafting may provide a safe and cost-effective means of reducing the risk of alloimmuniza-
tion. 
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Safe and effective blood transfusions are arguably one of 
the most important medical advances made in the past cen-
tury. These procedures are now common place and have 
saved millions of lives; however, until recently, this process 
has been of only limited interest to the research community. 
There is a substantial body of evidence showing that clinical 
problems can occur in chronically transfused patients be-
cause of alloimmunization [1–3]. These problems are com-
pounded by the fact that it is difficult, time-consuming and 
expensive to phenotype blood cells for mismatched antigens 
at non-ABO/RhD epitopes. Yet these mismatches can, and 
do, have a significant impact on patient care––especially for 
chronically transfused sickle cell and thalassemic patients. 
Indeed, by some estimates, up to 35% of sickle patients 
show clinically significant levels of alloimmunization (i.e., 
shortened RBC survival and mild fever) to non-ABO/RhD 
antigens [4,5]. Of these alloimmunized patients, some be-
come so reactive to donor RBCs that even the most closely 
matched samples cause a transfusion reaction, thus endan-
gering the life of the patient. 
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To address the problem of donor RBC alloimmunization, 
several clinical approaches have been suggested. These in-
terventions range from minimal preventative action (ad-
dressing the problems of alloimmunization only after it oc-
curs) to extensive prescreening of donor and recipient blood 
for the antigens most commonly associated with an in-
creased risk of alloimmunization [6,7]. This latter approach 
has been criticized because the screening process is expen-
sive and alloimmunization typically requires repeated anti-
gen exposure [8]. While this argument has economic merit, 
it is akin to not screening donor blood for transmissible dis-
ease and only treating the patient after they have been in-
fected. Therefore, the development of a cost-effective and 
practical means of reducing the risk of alloimmunization to 
all/most RBC alloantigens would be of significant clinical 
benefit. 
Ongoing work on the covalent modification of RBC and 
other blood cells with methoxypoly(ethylene glycol) 
(mPEG; PEGylation) suggests that polymer grafting may 
prove to be a practical prophylactic method of decreasing 
the risk of transfusional alloimmunization and a treatment 
for patients that have already been alloimmunized [9–20]. 
To further examine the potential clinical application of 
“immunocamouflaged” erythrocytes, the effects of polymer 
size on the antigenic recognition of non-ABO blood group 
antigens expressed by normal human RBCs was investi-
gated. Also, the immunocamouflage and immunogenic po-
tential of unmodified and PEGylated syngeneic, allogeneic 
and xenogeneic RBCs were examined in a murine transfu-
sion model. 
1  Materials and methods 
1.1  RBCs and human sera 
After obtaining informed consent, whole venous blood was 
drawn from normal healthy volunteers into heparin-con-     
taining Vacutainer tubes. To prevent storage artifacts, all 
samples were processed immediately. Care was taken to 
ensure adequate representation of males and females, and 
no individuals were excluded on the basis of race or gender. 
Erythrocytes were washed three times in isotonic saline 
prior to use. Serum was prepared from venous blood col-
lected in serum separator tubes (SST Vacutainer tubes; Bec-
ton Dickinson, Fairview, NJ, USA) and stored at −70°C. All 
biochemicals (unless stated otherwise) were obtained from 
Sigma Chemical Co. (St. Louis, MO, USA). 
1.2  Preparation of PEG-modified RBCs 
To assess the effect of molecular weight on the immuno-
camouflage of blood group antigens and intact RBCs, mono- 
functional (i.e., one binding site per chain) activated mPEGs 
of 2–30 kD were examined. Cyanuric chloride-activated 
mPEG (C-mPEG; 5 kD) and unactivated, soluble, mPEG 
(sol-mPEG; 5 kD) were obtained from Sigma. Methoxy-
poly(ethylene glycol)-benzotriazolyl carbonate (BTC-mPEG; 
5 and 20 kD) was obtained from Nektar Therapeutics (San 
Carlos, CA, USA). Succinimidyl valerate methoxy-
poly(ethylene glycol) (SVA-mPEG; 2, 5, 20 and 30 kD) 
was obtained from Laysan Bio Inc. (Arab, AL, USA). In 
addition, fluorescein-SVA-mPEG (fluor-SVA-mPEG; Lay-
san Bio Inc.) was used to visualize the homogeneity of 
polymer grafting. 
Washed human erythrocytes were covalently grafted with 
activated mPEGs as previously described [9–11,14]. Stock 
solutions of PEG-derivatives were made in PEG-buffer  
(50 mmol L−1 dibasic potassium phosphate, 105 mmol L−1 
NaCl, pH 8.0) and mixed with washed human erythrocytes 
(12% final hematocrit) using a micromixing device to 
assure homogeneous modification. Derivatization reactions 
were carried out at room temperature for 30 min or, in some 
cases, 60 min. Modified RBCs were then washed three 
times with phosphate buffered saline (PBS). A control 
group comprising RBC incubated in mPEG-free PEG-buffer 
(0 mmol L−1 mPEG-RBC) was used to determine the effects 
of blood processing on immune complex binding. RBCs 
incubated with sol-mPEG (i.e., incapable of membrane 
grafting) were included as an additional control.  
1.3  Two-phase partitioning 
Partitioning of control and PEG-modified RBCs was carried 
out in an aqueous two-phase system comprising PEG8000 
(Sigma) and Dextran T500 (molecular weight ~500000; 
Sigma) as previously described [13]. The concentrations of the 
PEG and Dextran stock solutions were determined by refrac-
tive index measurements. Control or modified RBCs were 
added to 1 mL of PEG8000 and mixed. An aliquot (0.5 mL) 
of the PEG-RBC mixture was then overlaid on 0.5 mL of 
Dextran T500 and mixed. The two-phase system was al-
lowed to separate at room temperature for 20 min prior to 
quantitation of the RBCs (via hemoglobin concentration) in 
the PEG layer. The results were expressed as the percentage 
of total hemoglobin in the upper PEG phase and were rep-
resentative of a minimum of three independent experiments. 
1.4  Anti-A/B antibody mediated RBC agglutination 
The effect of grafted polymers on anti-sera-mediated RBC 
agglutination was assessed using a modified platelet aggre-
gometer assay as previously described [9,10]. This assay 
allows the highly reproducible quantitation of the effects of 
PEGylation on anti-sera-mediated agglutination. Briefly, 
450 μL of control or PEGylated RBC (blood type A) sus-
pension (6% hematocrit in isotonic saline) were placed in an 
aggregometer cuvette at 37°C with stirring. Anti-A typing 
serum (or pooled human antiserum; 20 μL) was added and 
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RBC aggregation was monitored over time. 
1.5  Detection of blood group antigens by flow cytome-
try 
Blood typing antibodies, unless otherwise noted, were pur-
chased from Immucor, Inc. (Norcross, GA, USA). To quan-
titate the degree of immunocamouflage induced by the 
grafted polymers, flow cytometry (FACSCalibur; BD Bio-
sciences San Jose, CA, USA) was performed using previ-
ously established erythrocyte parameters [12–14]. A mini-
mum of 20000 cells was analyzed per sample. Control and 
PEG-modified RBCs were diluted to a 3% hematocrit in 
isotonic saline and resuspended in an equal volume of a 
specific anti-RBC antibody. The RBC-antibody mixtures 
were then incubated for 30 min at 37°C followed by wash-
ing twice with saline. A fluorescein isothiocyanate (FITC)-    
conjugated anti-human IgG-Fc specific secondary antibody 
(Sigma; 50 μL; diluted 1:50 in saline) was added to each 
sample tube and the mixtures incubated at 37°C for 30 min. 
The RBCs were washed twice in saline and fixed in 1% 
methanol-free formaldehyde (MFF). Immunocamouflage of 
blood group antigens was assessed using both Percent Gated 
and Mean Cell Fluorescence (MCF).  
1.6  In vivo RBC survival studies 
To examine the effects of the various mPEG derivatives in 
vivo, RBC survival studies were performed in Balb/c   
mice [9,12,13]. All animal studies were institutionally ap-
proved and conducted in compliance with all applicable 
Canadian animal care regulations. RBCs were collected 
from donor mice via cardiac puncture and derivatized with 
SVA-mPEG (20 kD) as previously described. The concentra-
tion of mPEG used for the in vivo studies ranged from 0 to  
2 mmol L−1, since murine RBCs are physically smaller (i.e., 
have fewer surface binding sites for mPEG) and more frag-
ile than human RBCs. Murine RBCs were labeled using the 
fluorescent membrane anchored marker, PKH-26 (Sigma). 
Blood samples from recipient mice were monitored until the 
labeled RBC was cleared from the circulation (approxi-
mately 50 d for unmodified syngeneic cells). Survival of 
fluorescently labeled mPEG-treated and control RBCs was 
monitored by analyzing the percentage of fluores-
cently-labeled RBCs in the peripheral circulation by flow 
cytometry. A minimum of five mice was used per mPEG 
concentration tested. 
1.7  In vivo RBC immunogenicity 
For in vivo immunogenicity studies, two genetically distinct 
mouse strains (C57Bl6 and Balb/c; H-2Kb and H-2Kd) were 
used to assess alloimmunization [21,22]. Donor RBCs were 
obtained from C57/Black or Balb/c mice by cardiac punc-
ture. To further assess the immunomodulatory effect of 
PEGylation, sheep RBCs were obtained from Cocalico 
(Reamstown, PA, USA). Mouse and sheep RBCs were 
washed three times in isotonic saline, and resuspended at a 
final concentration of 5 g% (~12% hematocrit). The RBC 
suspension was derivatized with C-mPEG at concentrations 
of 0, 1.2 and 5 mmol L−1 for 30 min at 4°C in PBS (pH 9.2). 
After derivatization, the cells were washed three times in 
isotonic saline and resuspended to a 50% hematocrit prior to 
transfusion. 
Recipient mice (Balb/c; n=24) were transfused intraperi-      
toneally (i.p.) with 500 μL of control or mPEG-modified 
C57Bl/6 or Balb/c RBCs. This procedure was repeated for 
up to three transfusions (each at ~50 d intervals). At the end 
of each transfusion, eight mice per group were sacrificed 
and serum was collected for analysis of anti-donor antibody 
formation. Sera from four mice were pooled, while the re-
maining four mice were analyzed separately (to assess re-
sponse variation) for IgG and IgM antibodies against the 
transfused RBCs. Antibody binding was quantitated by 
mixing 600 μL of serum with saline (at ratios of 2:1, 1:1, 
and 1:5) with 200 μL of an 80% hematocrit of unmodified 
donor RBCs. The samples were mixed for 30 min at 37°C 
and then washed three times in isotonic saline. Secondary 
antibodies to mouse IgG (PE labeled) and IgM (FITC-labeled) 
were added to 20 μL of the previously incubated packed 
RBCs and mixed for 30 min at 37°C followed by washing 
three times in isotonic saline. Secondary antibody binding 
was quantitated by flow cytometry as described above. 
The immunogenicity of control and PEGylated xeno-
geneic sheep RBC was similarly assessed in Balb/c mice. 
Mouse serum was collected 14 d after the primary transfu-
sion of sheep RBCs and the presence of mouse anti-sheep 
RBC IgG and IgM was assessed by flow cytometry. In 
addition, some mice received a second transfusion of 
sheep cells (14 d after the primary transfusion) and serum 
was collected 28 days post-primary transfusion and as-
sessed for anti-sheep IgG and IgM. Mice were transfused 
with a blood volume approximating 10% of the total 
mouse blood volume and each group contained a minimum 
of eight mice. 
1.8  Statistical analysis 
All results were expressed as the mean±standard error of the 
mean (SEM) unless otherwise stated. Each experiment was 
repeated a minimum of three times although, in some cases 
(e.g., microscopy), representative samples are presented. 
Statistical analysis was performed using SPSS v.16.0 statis-
tical software (SPSS Inc., Chicago, IL, USA). One-way 
analysis of variance (ANOVA) followed by Tukey’s post-     
hoc test was performed for comparison of three or more 
mean values. An independent variable t-test was used for 
comparison of two mean values. A two-tailed P-value<0.05 
was considered significant. 
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2  Results 
Biophysically, membrane grafted polymers alter the surface 
characteristics of cells as denoted by changes in separation 
profiles in a two-phase (Dextran-PEG) partitioning system. 
As shown in Figure 1A, the biophysical partitioning of 
modified RBCs is dependent upon both grafting concentra-
tion and polymer size. However, large polymers more effec-
tively shifted the modified RBCs into the PEG layer, even at 
very low grafting concentrations. As shown, grafting of the  
2 kD polymer only resulted in significant partitioning of the 
RBCs to the PEG layer at higher grafting concentrations. 
By contrast, the 20 and 30 kD SVA-mPEG modified RBCs 
rapidly moved into the PEG layer, even at very low grafting 
concentrations, with maximal partitioning occurring at  
≥0.5 mmol L−1. Moreover, even at relatively modest grafting 
concentrations (1 mmol L−1 SVA-mPEG-20 kD) RBCs were 
uniformly derivatized, as shown by overlay of light and 
fluorescent photomicrographs of the SVA-mPEG-RBC 
relative to the control cells (Figure 1B). Importantly, linker 
chemistry (as shown by the 5 kD C- and SVA-mPEG) was 
not a significant factor in phase separation as long as the 
linker chemistries showed similar reactivity and hydrolysis 
rates. 
Polymer length was also important in preventing anti-
genic recognition of the A/B antigens on RBCs. As shown 
in Figure 2, polymer lengths of 2, 5 and 20 kD all conferred 
some degree of protection against antisera-mediated agglu-
tination of type A RBCs. This protection against antibody-        
mediated agglutination was both size- and dose-dependent, 
with long chain polymers providing significantly better in-
hibition of agglutination (Figure 2A–C). This finding corre-
lates well with the observed partitioning of RBCs in the 
PEG-Dextran two-phase system. As noted in Figure 2C, 
grafting concentrations ≥1.2 mmol L−1 of the 20 kD poly-
mer resulted in the complete loss of anti-A-mediated aggluti-       
nation. Grafting efficacy was also highly malleable in terms 
of both pH and the grafting time of the PEGylation reaction 
(Figure 2D). No statistically significant difference was ob-
served between pH 8.0 and 9.2 after either 30 or 60 min of 
derivatization (2.5 mmol L−1 5 kD SPA-mPEG). Similarly, 
while a 60-min grafting reaction appeared to confer some 
advantages in terms of inhibiting anti-A agglutination, this 
observed difference (2.5 mmol L−1 5 kD SPA-mPEG) was 
not significant when the effect of time was assessed using 
the control cells (0 mmol L−1 SPA-mPEG).  
While immunocamouflage of A/B antigens was observed, 
it was not sufficient to yield a true “universal erythrocyte” 
as the method cannot remove all risk from an untyped blood 
recipient. However, immunocamouflage of the non-ABO 
blood group antigens holds much greater clinical potential. 
The Rhesus blood group antigens, especially RhD, are par-
ticularly important in transfusion medicine. As shown in 
Figure 3, RhD, Rhc, and RhE are all effectively camou-
flaged by grafted mPEG. Immunocamouflage of the D, c, 
and E antigens is dependent upon both grafting concentra-
tion and polymer size. Immunocamouflage of antigenic 
epitopes is shown by the absolute camouflage (Percent  
 
 
Figure 1  Polymer grafting results in size- and concentration-dependent phase separation. A, mPEG-RBCs preferentially partition to the PEG layer of a 
two-phase Dextran-PEG separation system. Larger polymers (20 and 30 kD) significantly (P<0.001) enhance the separation compared with equimolar con-
centrations of small-chain (2 or 5 kD) polymers. Separation efficacy correlates well with the extent of immunocamouflage imparted by the grafted polymer. 
B, Additionally, the grafted polymer provides uniform coverage of the modified RBCs, as shown by the grafted fluorescent SVA-mPEG (20 kD; 1 mmol L−1) to 
human RBC relative to the control RBCs. Differential interference contrast microscopy was used to assess the control and modified RBCs. Representative  
fields are shown. 
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Figure 2  RBC agglutination is dramatically affected by both the chain length and grafting concentration of the mPEG polymer. Shown is a comparison of 
solution-phase agglutination studies using anti-A antisera and type A RBCs modified with different chain lengths of SPA-mPEG: 2 kD (A), 5 kD (B) and 20 
kD (C). All sizes of SPA-mPEG polymers are able to decrease RBC agglutination. However, the molar concentration necessary to inhibit agglutination dra-
matically decreases as the polymer length increases. These three panels are representative of >5 independent assays. D, Changes in derivatization time and  
pH do not significantly impact polymer grafting as assessed by anti-A agglutination. 
Positive Cells; Figure 3A–C) and the change in MCF (Fig-
ure 3A and B, inserts). As shown, polymer size is an im-
portant factor in the efficacy of immunocamouflage by the 
20 kD polymer, which showed significantly better efficacy 
in terms of percent antigen positive cells than the 2 
(P<0.001) or 5 (P<0.01) kD polymers at intermediate (2–3 
mmol L−1) grafting concentrations. Relative to the percent 
positive RBCs, the MCF of modified cells was even more 
dramatically affected by the size of the grafted polymer. 
Compared with either the 2 or 5 kD chains, the 20 kD 
polymer very effectively camouflaged the bulk of RhD and 
Rhc antigens, as shown by the decrease in antibody binding. 
A decrease in the MCF would significantly impact the anti-
genic presentation efficacy of the donor cells. Importantly, 
as was noted in Figure 1, linker chemistry was not a sig-
nificant factor, as both the 5 kD C and BTC-mPEGs and the 
20 kD SPA- and BTC-mPEGs yielded relatively comparable 
results. The small differences that were observed relative to 
linker chemistry are readily explained by the hydrolysis 
half-life of the linker chemistries (13.5 and 16.5 min for 
BTC- and SPA-mPEGs, respectively) and the 60-min deri-
vatization time used in the experiments. 
Other, non-ABO, blood group antigens from the Kidd 
(Jka, Jkb), Kell (k) and Duffy (Fya) families were also effi-
ciently camouflaged by the grafted polymers. As shown in 
Figure 4, Jka, Jkb, k, and Fya were all camouflaged by the 2, 
5 and 20 kD grafted polymers. However, all polymer sizes 
were not equally effective at masking all blood group anti-
gens. Of the blood groups shown in Figure 4, k was the 
most easily camouflaged––even by the 2 kD polymer. By 
contrast, the 2 kD polymer failed to immunocamouflage Jkb 
(P>0.05) and provided only weak, though statistically sig-
nificant (P<0.05), protection to the Jka blood group antigen. 
The 20 kD polymer provided highly significant (P<0.001) 
levels of protection for both Jka and Jkb, though it provided 
better protection for Jka. Hence, the nature of the antigen 
(height relative to the membrane surface) is a critical deter-
minant in the choice of polymer. 
While in vitro assays demonstrate the efficacy and poten-
tial clinical value of immunocamouflaged RBCs, in vivo 
efficacy and stability are both crucial for evaluating poten-
tial utility. Importantly, immunocamouflage of RBCs did  
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Figure 3  Rh blood group antigens are effectively immunocamouflaged by grafted polymers. Anti-RhD (A) and Anti-Rhc (B) and RhE (C) antibody bind-
ing is dramatically attenuated by mPEG-modification, as shown by a decrease in percent positive cells and MCF (A and B, inserts). The decrease in binding 
was a function of both grafting concentration (0–5 mmol L−1) and polymer size (2, 5 or 20 kD). Importantly, as shown in the MCF inserts in A and B, unac-
tivated mPEG (sol-mPEG) had no immunocamouflage effect (denoted by the labeled dashed line). Human RBCs were modified with 0–5 mmol L−1 activated  
mPEG as described in Materials and methods. Results represent the mean±SD of a minimum of three independent experiments. 
 
 
Figure 4  Derivatization of RBC with mPEG effectively attenuates antibody recognition of non-ABO antigens as shown on selected Kidd (Jka, Jkb; A and 
B, respectively), Kell (k; C) and Duffy (Fya; D) antigens. The effects of 2, 5 and 20 kD polymers on antibody binding to blood group positive human RBCs 
are shown. A minimum of 20000 counts per samples was analyzed by flow cytometry. The MCF of the antibody-positive cells also decreased dramatically  
for all blood group antigens (data not shown). 
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not adversely affect in vivo survival in a murine transfusion 
model. Figure 5A shows both the mean clearance curves for 
PKH-26-labeled control and polymer-modified (2 mmol L−1 
BTC-mPEG) RBCs and the clearance curves of the indi-
vidual mice (n=5 per group). As noted, no significant dif-
ferences were observed between the groups and both popu-
lations fell within normal murine clearance patterns. Fur-
thermore, Figure 5B shows that immunocamouflage of 
syngeneic donor cells did not induce the formation of 
neoantigens, or expose cryptoantigens, which would have 
resulted in immune recognition and clearance by the recipi-
ent mice. This was demonstrated by a lack of IgG (shown) 
and IgM (not shown) antibody production to either the con-
trol or mPEG-RBCs over the course of 1–3 transfusions (up 
to ~180 d). More importantly, with regards to the potential 
clinical utility of immunocamouflaged RBC, polymer modi-
fied allogeneic (C57Bl/6 into Balb/c) RBCs showed a highly 
significant (P<0.001) blunting of antibody production relative 
to the unmodified allogeneic donor cells (Figure 5C). This 
effect remained potent after three transfusions with modi-
fied allogeneic donor RBCs (~180 d). In contrast to 
mPEG-RBCs, unmodified allogeneic RBCs induced a sig- 
 
 
Figure 5  Effects of polymer modification of RBCs on in vivo survival and immunogenicity of syngeneic, allogeneic and xenogeneic donor cells. A, Syn-
geneic primary transfusions. The clearance rates after primary transfusion of control (open squares) and BTC-mPEG-derivatized (20 kD; solid squares) mur-
ine RBCs. PEGylated RBCs were tagged with a fluorescent fatty acid marker (PKH-26) and survival was followed by flow cytometry. The results represent 
the mean±SEM of five Balb/c mice per PEG concentration. The insert shows the clearance curves of each individual mouse. B, Neo-antigen formation was 
not observed upon transfusion with PEGylated RBCs. The percentage of IgG-positive RBCs, subsequent to 1–3 transfusions with control or PEGylated (1.2 
or 5 mmol L−1 C-mPEG) syngeneic donor cells, is shown. Murine IgG-positive RBCs were detected by flow cytometry using a fluorescent-labeled 
anti-mouse IgG secondary antibody. C, The immunogenicity of allogeneic RBCs was significantly (P<0.001) reduced by PEGylation of the donor cells, even 
after three challenges with the modified allogeneic donor cells. As shown, mice receiving unmodified donor cells produced significant amounts of IgG (but 
not IgM) in response to the allogeneic cells. This was not observed for the mPEG-RBCs. Recipient IgG (shown) and IgM (not shown) antibodies to the al-
logeneic cells were detected by flow cytometry. D, As an extreme test of the ability of immunocamouflage to prevent immunogenic recognition of donor 
cells, xenogeneic sheep RBCs (sRBCs) were PEGylated (1.2 or 5 mmol L−1 C-mPEG). Following primary or secondary transfusion of mice with unmodified 
sRBCs, a potent IgG antibody response was noted 14 days post challenge. However, PEGylation of the donor sRBCs dramatically reduced (P<0.001) the 
IgG response. This effect was maintained even after a second transfusion was administered on day 14, and assessed on day 28 following primary exposure. 
A–D, Mice were transfused with a blood volume approximating 10% of the total mouse blood volume. Each group contained eight mice and the results  
shown represent the mean number of positive RBCs±SD. 
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nificant antibody response, though it should be noted that 
these antibodies did not significantly affect donor cell cir-
culation time. The immunocamouflaging effect of the 
grafted polymers also provided a potent (P<0.001) im-
munoprotective effect on xenogeneic (sheep) RBCs (Figure 
5D). 
3  Discussion 
Despite ABO/RhD matching, the RBC remains an antigeni-
cally challenged cell. Adverse reactions, ranging from clini-
cally insignificant to significant, arising from non-ABO/RhD 
antigens are relatively common, due in large part to varying 
expression of these epitopes by different ethnic and racial 
groups [4,23]. Indeed, transfusion reactions arising from the 
non-ABO/RhD blood group antigens are most commonly 
encountered in minority populations. Coupled with this is 
the finding that the incidence of alloimmunization is also 
positively correlated with the number of transfusions an 
individual receives. Hence, alloimmunization to non-ABO/     
RhD blood group antigens is exaggerated in certain indi-
viduals, especially minorities, with chronic diseases (e.g., 
sickle cell disease or thalassemia) receiving transfusion 
therapy [1,4,24]. 
Consequent to alloimmunization, transfusion reactions 
against non-ABO/RhD RBC antigens can make it almost 
impossible to identify appropriate blood donors [25]. To 
prevent the risk of extreme alloimmunization, various clini-
cal interventions have been explored. These include the now 
standard use of packed RBCs in place of whole blood (to 
prevent alloimmunization due to white blood cells), exten-
sive pre-transfusion phenotype screening to more closely 
match donor and patient RBCs, and the long-term use of  
single RBC donors. Despite these often costly measures, 
clinically significant alloimmunization rates can still exceed 
30% in patients with sickle cell anemia and thalassemia [26]. 
Consequently, many laboratories and clinicians question the 
cost effectiveness of donor screening as a prophylactic 
measure to prevent alloimmunization. 
Hence, a cost effective means of diminishing/preventing 
the risk of alloimmunization is urgently needed. To this end, 
immunocamouflaged RBCs may prove to be of clinical 
value [20]. As shown in the present study, immunocamou-
flaged RBCs are characterized by global camouflage of the 
ABO and non-ABO human blood group antigens (Figures 
2–4) and a significant attenuation of donor cell immuno-
genicity (Figure 5) in a murine transfusion model. This is 
effectively accomplished at dosages that do not adversely 
affect the in vitro or in vivo stability and function of human 
or murine RBCs. In addition, the procedure is inexpensive 
and can be readily adapted to existing blood banking tech-
nology.  
While the moderate derivatization concentrations (≤2.5 
mmol L−1 mPEG per 0.6×109 RBC mL−1) that are likely to 
be used for human RBC do not completely camouflage the 
A/B blood group antigens, these grafting concentrations do 
result in significant masking of clinically relevant non-ABO 
antigens. Importantly, it is not necessary to achieve a state 
of complete immunocamouflage to significantly reduce the 
risk of alloimmunization due to these non-ABO blood 
groups. As shown in Table 1, the observed risk of alloim-
munization is governed, in part, by the number of cells 
positive for a particular antigen, the apparent antigen den-
sity of the antigen on the cell, and the ability of appropriate 
antigen presenting cells to recognize, phagocytose and pre-
sent that antigen. PEGylation of donor RBCs dramatically 
reduces the efficiency of each of these steps: The number of  
Table 1  Antigenic abundance and relative immunogenicity of selected blood group antigensa) 
Blood group Antigen Percent immunogenicity* Hemolytic transfusion reaction Primary Ab Copies per RBC 
ABO A, B 100Ac Yes IgM 1×106 
Rh D 50.00 Yes IgG 10000−35000** 
 c 2.05 Yes IgG 37000−85000** 
 E 1.69 Yes IgG 450−25600** 
 e 0.56 Yes IgG 13400−24400** 
 C 0.11 Yes IgG 42000−56000*** 
Kidd Jka 0.07 Yes IgG 11000−14000# 
 Jkb 0.03 Yes IgG 11000−14000# 
Duffy Fya 0.23 Yes IgG 7000−13000# 
Kell k 1.50 Yes IgG 3500 
 K 5.00 Yes IgG 6000 
MNS S 0.04 Yes IgG >12000 
 s 0.03 Yes IgG 12000 
a) Modified from Martin [27]. The antigenic sites are presented as ranges because the number expressed is dependent upon the absence or presence of 
other antigens. *, percentage of null recipients sensitized after a single transfusion. Ac, acute transfusion reaction. **, from Hughes-Jones et al. [28]; ***, 
from Masouredis et al. [29]; #, from Skov [30]. 
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antigen positive cells is reduced, the apparent antigen den-
sity on the positive cells is decreased, PEGylated cells are 
less effectively phagocytosed, and antigen presentation of 
PEGylated proteins is impaired [9,20–22,31]. 
The net result of these events on clinical practice may be 
illustrated by examining the potential effects that immuno-
camouflaged RBCs may have on the risk of alloimmuniza-
tion to Rhc. Table 1 shows that ‘clinical experiments’ (i.e., 
unintentional mismatches at specific antigens) determine the 
relative risk of immunogenic recognition for Rhc to be ap-
proximately 2% after a single mismatch [28–30]. As noted 
in Figure 3, Rhc is readily camouflaged by mPEG-grafting, 
as shown by a decrease in both percent positive cells and 
MCF. This finding raises the question: What would be the 
residual alloimmunization risk of Rhc+ donor RBCs subse-
quent to polymer grafting (e.g., 2.5 mmol L−1 of a 20 kD 
polymer)? Our in vivo murine data (Figure 5) with alloge-
neic and xenogeneic donor cells suggests that the actual risk 
of alloimmunization would be significantly reduced. Hence, 
the 2% risk of immunogenic recognition may subsequently 
become a 0.2 or a 0.02% risk of alloimmunization. Thus, 
while some individuals will become alloimmunized, even 
after receiving PEGylated blood, the relative risk to an indi-
vidual, and to the chronically transfused patient population 
as a whole, will be dramatically reduced. 
Indeed, mPEG-RBCs (syngeneic, allogeneic and xeno-
geneic) show decreased immunogenicity. A number of 
studies show that, while PEG has low immunogenic poten-
tial, it does (under some circumstances) induce anti-PEG 
antibodies [32–35]. Typically, in animal models this has 
required the co-administration of Freund’s Complete Ad-
juvant or coupling of PEG to highly immunogenic pro-
teins [32,33]. More recently, studies have reported that a 
significant percentage of normal blood donors show evi-
dence of anti-PEG antibodies [34,35]. However, most 
long-term studies on PEGylated human enzymes have failed 
to report any significant anti-PEG effects. Moreover, no an-
tibody response (either IgG or IgM) was noted in response to 
donor syngeneic mPEG-RBC in the murine transfusion 
model used in the present study. Indeed, repeated transfusion 
of syngeneic mPEG-RBCs showed no increased clearance in 
our murine model. More importantly, highly immunogenic 
allogeneic and xenogeneic cells demonstrated significantly 
decreased murine antibody responses in recipient mice. 
In summary, global camouflage of RBC antigens by 
methoxypoly(ethylene glycol) derivatization dramatically 
attenuates both recognition of blood group antigens and the 
in vivo immunogenicity of antigenically disparate cells. 
Immunocamouflage arises from the biophysical effects of 
the grafting polymer, which both attenuates cell surface 
charge (hindering receptor-ligand interactions) and steri-
cally impedes the approach and binding of antibodies and/or 
cells [20,36]. These data clearly suggest that PEGylation of 
non-ABO/RhD matched RBCs effectively reduces the risk 
of alloimmunization in chronically transfused patients. Ap-
plication of this technology may be clinically useful in 
chronically transfused sickle and thalassemic patients be-
cause of the increased risk of alloimmunization faced by 
these patient populations. 
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